Báo cáo sinh học: " Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients | Kilvaer et al. Journal of Translational Medicine 2011 9 104 http content 9 1 104 JOURNAL OF TRANSLATIONAL MEDICINE RESEARCH Open Access Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients I p. ws 1 l l z r1A z l I -s I lzz W Ĩ1 2 Ct ro I I I r i Ạ c f V L t f2 E c m z Iz l4 D S r A A D VC m r-3 4 inomas K Kilvaer Andrej valKov Sveinung W Sorbye Elvina Smeland Roy M Bremnes Lill-Tove Busund1 2 and Tom Donnem3 4 Abstract Background Non-gastrointestinal stromal tumor soft-tissue sarcomas non-GIST STSs constitute a heterogeneous group of tumors with poor prognosis. Fibroblast growth factor 2 FGF2 and fibroblast growth factor receptor-1 FGFR-1 in close interplay with platelet-derived growth factor-B PDGF-B and vascular endothelial growth factor receptor-3 VEGFR-3 are strongly involved in angiogenesis. This study investigates the prognostic impact of FGF2 and FGFR-1 and explores the impact of their co-expression with PDGF-B and VEGFR-3 in widely resected tumors from non-GIST STS patients. Methods Tumor samples from 108 non-GIST STS patients were obtained and tissue microarrays were constructed for each specimen. Immunohistochemistry was used to evaluate the expressions of FGF-2 FGFR-1 PDGF-B and VEGFR-3. Results In the multivariate analysis high expression of FGF2 P HR 95 CI and the co-expressions of FGF2 PDGF-B overall P intermediate P HR 95 CI high P HR 95 CI and FGF2 VEGFR-3 overall P intermediate P HR 95 CI high P HR 95 CI were significant independent prognostic indicators of poor disease-specific survival. Conclusion FGF2 alone or in co-expression with PDGF-B and VEGFR-3 is a significant independent negative prognosticator in widely resected non-GIST STS patients. Introduction Soft-tissue sarcomas STSs constitute a group of tumors of mesenchymal lineage comprising over 50 histological entities 1 . .